<DOC>
	<DOCNO>NCT02945800</DOCNO>
	<brief_summary>The purpose study see nab-paclitaxel combined gemcitabine prevents formation growth tumor participant relapse refractory osteosarcoma , Ewing sarcoma , rhabdomyosarcoma soft tissue sarcoma measure length time treatment disease get bad . Researchers also want find nab-paclitaxel combine gemcitabine safe tolerable .</brief_summary>
	<brief_title>Nab-Paclitaxel Gemcitabine Recurrent/Refractory Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Participants must age ≥ 12 ≤ 30 year , histologic diagnosis osteosarcoma , Ewing sarcoma , rhabdomyosarcoma nonrhabdomyosarcoma soft tissue sarcoma either diagnosis relapse . Must experience relapse frontline therapy , document disease progression frontline therapy . Must measurable disease assess use Response Evaluation Solid Tumors ( RECIST ) 1.1 , define presence least one lesion MRI CT scan accurately measure long diameter 10 mm least one dimension . For phase II trial , patient disease limited bone marrow metastases NOT eligible , disease site assessed RECIST 1.1 criterion . Must relapse refractory cancer know curative option . Prior Therapy : There limit number prior therapy provide eligibility criterion meet . However , participant must recover acute toxic effect prior treatment . ( A ) Must receive prior therapy either gemcitabine nabpaclitaxel . ( B ) Myelosuppressive chemotherapy : Must receive myelosuppressive chemotherapy within 3 week protocol therapy study . ( C ) Hematopoietic growth factor : 7 day must elapse start protocol therapy since completion therapy filgrastim , 14 day must elapse start protocol therapy receive pegfilgrastim . ( D ) Biologic ( antineoplastic agent ) : 7 day must elapse start protocol therapy since completion therapy biologic agent . ( E ) Monoclonal antibody : 3 halflives must elapse start protocol therapy since prior therapy include monoclonal antibody . ( F ) Radiotherapy : 2 week must elapse start protocol therapy since local palliative radiotherapy ( small port ) ; 3 month must elapse 50 % radiation pelvis ; 6 week must elapse substantial bone marrow irradiation give . ( G ) Stem Cell Transplant Rescue : No evidence active graft vs. host disease 2 month must elapse start protocol therapy since transplant . Karnofsky performance score must ≥ 60 Must organ marrow function Neuropathy : Must ≤ grade 1 neuropathy enrollment Central nervous system ( CNS ) Metastases : Potential participant know CNS metastasis exclude unless treat surgically radiotherapy stable recurrent lesion least 3 month start protocol therapy . Contraception : Women childbearing potential men must agree use adequate contraception prior study entry duration study participation . Men treat enrol protocol must also agree use adequate contraception 4 month completion gemcitabine nabpaclitaxel administration . Consent : Participants must ability understand willingness sign write informed consent assent document . Potential participant receive investigational agent Must receive additional medicine give specific purpose treat cancer A history allergic reaction attribute docetaxel paclitaxel Concomitant Medications : The metabolism paclitaxel catalyze CYP2C8 CYP3A4 . The following medicine avoid study ability inhibit induce CYP2C8 CYP3A4 : A ) Inhibitors : ketoconazole imidazole antifungal , erythromycin , fluoxetine , gemfibrozil , cimetidine , ritonavir , saquinavir , indinavir , nelfinavir . B ) Inducers : Rifampicin , carbamazepine , phenytoin , efavirenz , nevirapine . C ) Potential participant receive medication ineligible . Potential participant ineligible uncontrolled intercurrent illness include , limited : ongoing active infection ; symptomatic congestive heart failure ; unstable angina pectoris ; cardiac arrhythmia ; psychiatric illness/social situation would limit compliance study requirement . Pregnant breastfeed HIV Infection : HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction study medication . Anyone opinion investigator may able comply safety monitoring requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>soft tissue</keyword>
	<keyword>bone joint</keyword>
	<keyword>non-rhabdomyosarcoma soft tissue sarcoma</keyword>
	<keyword>pediatric</keyword>
</DOC>